Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
The need for improved health care transition (HCT) for youth with autism spectrum disorder (ASD) can be met with training for health care professionals, financial counseling for parents of children with ASD, and increased vocational training and opportunities for youth with ASD.
AMA J Ethics. 2015;17(4):342-347. doi:
10.1001/journalofethics.2015.17.4.pfor1-1504.